The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population
Journal of Oncology · 23.11.2022 · 2022 · 1-11
DOI: 10.1155/2022/4324635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 23.11.2022. Verfasst von German Calderillo Ruiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Oncology Unit, Instituto Nacional de Cancerologia, Mexico, Mexico. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Survival and recurrence rates following locoregional colon cancer surgical resection are highly variable. Currently used tools to assess patient risk are still imperfect. In the present work, we evaluate, for the first time, the prognostic value of the recently developed HALP (hemoglobin, albumin, lymphocyte, and platelet) index in Hispanic colon cancer patients. Patients and Methods. We conducted a retrospective cohort study in Mexican patients with a nonmetastatic colon cancer diagnosis who underwent surgical resection. We determined the preoperative HALP score optimal cut-off value by using the X-tile software. We plotted survival curves using the Kaplan–Meier method and performed a multivariate Cox regression analysis to explore the association of preoperative HALP score with two primary endpoints: overall survival (OS) and disease-free survival (DFS).
Results
We included 640 patients (49.8% female). The optimal HALP cut-off value was 15.0. A low HALP index was statistically significantly associated with a higher TNM stage. Low HALP score was statistically significantly associated with shorter median OS in the Kaplan–Meier analysis (73.5 vs. 84.8 months) and in the multivariate Cox regression analysis (HR = 1.942, 95% CI = 1.647–2.875). There was no significant association between the HALP score and DFS.
Conclusions
Our findings show that the HALP index is an independent factor associated with survival in Hispanic patients, despite recurrence. It seems to reflect both the anatomical extent of the disease and traditionally unaccounted nutritional and inflammatory factors that are significant for prognosis.
Autor:innen und Institutionen
- Gastrointestinal Oncology Unit, Instituto Nacional de Cancerologia, Mexico, Mexico.
- Universidad Nacional Autonoma de Mexico, Mexico, Mexico.
- School of Medicine, Benemerita Universidad Autonoma de Puebla, Puebla, Mexico.
- School of Medicine, Universidad Panamericana, Mexico, Mexico.
ORCID-Profile: German Calderillo Ruiz, Horacio Lopez Basave, Rafael Sebastian Vazquez Renteria, Alison Castillo Morales, Alberto Guijosa, Carolina Castillo Morales, Marytere Herrera, Consuelo Diaz, Ezequiel Vazquez Cortes, Erika Ruiz-Garcia, Wendy R Munoz Montano
Zitieren
APA
Calderillo Ruiz, G., Lopez Basave, H., Vazquez Renteria, R. S., Castillo Morales, A., Guijosa, A., Castillo Morales, C., Herrera, M., Diaz, C., Vazquez Cortes, E., Ruiz-Garcia, E., & Munoz Montano, W. R. (2022). The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population. Journal of Oncology, 2022, 1-11. https://doi.org/10.1155/2022/4324635
Vancouver
Calderillo Ruiz G, Lopez Basave H, Vazquez Renteria RS, Castillo Morales A, Guijosa A, Castillo Morales C, et al. The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population. Journal of Oncology. 2022;2022:1-11. doi:10.1155/2022/4324635
BibTeX
@article{CalderilloRuiz2022,
author = {Calderillo Ruiz, German and Lopez Basave, Horacio and Vazquez Renteria, Rafael Sebastian and Castillo Morales, Alison and Guijosa, Alberto and Castillo Morales, Carolina and Herrera, Marytere and Diaz, Consuelo and Vazquez Cortes, Ezequiel and Ruiz-Garcia, Erika and Munoz Montano, Wendy R},
title = {The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population},
journal = {Journal of Oncology},
year = {2022},
volume = {2022},
pages = {1--11},
doi = {10.1155/2022/4324635}
}
EUVIMED